Novel structure-based and combinatorial approaches for RET-fusion NSCLC

Grant title (if any)
Hamoui Foundation / LUNGevity Lung Cancer Research Award
John Heymach, MD, PhD
The University of Texas MD Anderson Cancer Center

There is an urgent need to identify new agents or combination therapies to benefit patients whose tumors have developed resistance to current RET inhibitors. Currently, the true extent of RET-dependent (resistance mutations in the RET gene) versus RET-independent mechanisms of resistance is unknown. Dr. Heymach’s team will study mechanisms and biomarkers of RET-independent drug resistance and test different drug combinations to overcome RET inhibitor resistance.